volume 11 issue 10 pages 1677-1694

Mechanisms of fenretinide-induced apoptosis

Publication typeJournal Article
Publication date2006-07-15
scimago Q1
wos Q1
SJR2.233
CiteScore10.6
Impact factor8.1
ISSN13608185, 1573675X
Cancer Research
Pharmacology
Cell Biology
Pharmaceutical Science
Clinical Biochemistry
Biochemistry (medical)
Abstract
Fenretinide, a synthetic retinoid, has emerged as a promising anticancer agent based on numerous in vitro and animal studies, as well as chemoprevention clinical trials. In vitro observations suggest that the anticancer activity of fenretinide may arise from its ability to induce apoptosis in tumor cells. Diverse signaling molecules including reactive oxygen species, ceramide, and ganglioside GD3 can mediate apoptosis induction by fenretinide in transformed, premalignant, and malignant cells. In many cell types, these signaling intermediates appear to be induced by mechanisms that are independent of retinoic acid receptor activation, and ultimately initiate the intrinsic or mitochondrial-mediated pathway of cell elimination. Numerous investigations conducted during the past 10 years have discovered a great deal about the apoptogenic activity of fenretinide. In this review we explore the mechanisms associated with fenretinide-induced apoptosis and highlight certain mechanistic underpinnings of fenretinide-induced cell death that remain poorly understood and thus warrant further characterization.
Found 
Found 

Top-30

Journals

1
2
3
4
5
PLoS ONE
5 publications, 3.16%
International Journal of Molecular Sciences
4 publications, 2.53%
Molecular Cancer
4 publications, 2.53%
Biochemical Pharmacology
4 publications, 2.53%
Cancer Letters
3 publications, 1.9%
Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
3 publications, 1.9%
Carcinogenesis
3 publications, 1.9%
Antioxidants and Redox Signaling
2 publications, 1.27%
Oncology Letters
2 publications, 1.27%
International Journal of Oncology
2 publications, 1.27%
Anti-Cancer Drugs
2 publications, 1.27%
Investigational New Drugs
2 publications, 1.27%
Apoptosis : an international journal on programmed cell death
2 publications, 1.27%
Pharmaceutical Research
2 publications, 1.27%
Biochemical and Biophysical Research Communications
2 publications, 1.27%
Journal of Biological Chemistry
2 publications, 1.27%
Bioorganic and Medicinal Chemistry Letters
2 publications, 1.27%
Free Radical Biology and Medicine
2 publications, 1.27%
FASEB Journal
2 publications, 1.27%
Molecular Nutrition and Food Research
2 publications, 1.27%
Molecular Pharmaceutics
2 publications, 1.27%
Journal of Cancer Therapy
2 publications, 1.27%
Pharmaceutical Development and Technology
2 publications, 1.27%
The Scientific World Journal
2 publications, 1.27%
BioMed Research International
2 publications, 1.27%
Molecular Cancer Therapeutics
2 publications, 1.27%
Cancer Research
2 publications, 1.27%
Comprehensive Physiology
2 publications, 1.27%
Biochemistry and Cell Biology
1 publication, 0.63%
1
2
3
4
5

Publishers

5
10
15
20
25
30
35
40
45
Elsevier
44 publications, 27.85%
Springer Nature
21 publications, 13.29%
Wiley
16 publications, 10.13%
Hindawi Limited
7 publications, 4.43%
MDPI
6 publications, 3.8%
American Association for Cancer Research (AACR)
6 publications, 3.8%
Taylor & Francis
5 publications, 3.16%
Public Library of Science (PLoS)
5 publications, 3.16%
Spandidos Publications
4 publications, 2.53%
American Chemical Society (ACS)
4 publications, 2.53%
American Society for Biochemistry and Molecular Biology
3 publications, 1.9%
Oxford University Press
3 publications, 1.9%
Mary Ann Liebert
2 publications, 1.27%
Ovid Technologies (Wolters Kluwer Health)
2 publications, 1.27%
Federation of American Societies for Experimental Biology (FASEB)
2 publications, 1.27%
Scientific Research Publishing
2 publications, 1.27%
American Society for Microbiology
2 publications, 1.27%
Canadian Science Publishing
1 publication, 0.63%
SAGE
1 publication, 0.63%
Frontiers Media S.A.
1 publication, 0.63%
SLACK
1 publication, 0.63%
American Society of Animal Science
1 publication, 0.63%
Walter de Gruyter
1 publication, 0.63%
American Physiological Society
1 publication, 0.63%
American Society of Hematology
1 publication, 0.63%
American Diabetes Association
1 publication, 0.63%
Cold Spring Harbor Laboratory
1 publication, 0.63%
Bentham Science Publishers Ltd.
1 publication, 0.63%
5
10
15
20
25
30
35
40
45
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
158
Share
Cite this
GOST |
Cite this
GOST Copy
Hail N., Kim H., Lotan R. Mechanisms of fenretinide-induced apoptosis // Apoptosis : an international journal on programmed cell death. 2006. Vol. 11. No. 10. pp. 1677-1694.
GOST all authors (up to 50) Copy
Hail N., Kim H., Lotan R. Mechanisms of fenretinide-induced apoptosis // Apoptosis : an international journal on programmed cell death. 2006. Vol. 11. No. 10. pp. 1677-1694.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1007/s10495-006-9289-3
UR - https://doi.org/10.1007/s10495-006-9289-3
TI - Mechanisms of fenretinide-induced apoptosis
T2 - Apoptosis : an international journal on programmed cell death
AU - Hail, N
AU - Kim, H.J.
AU - Lotan, R.
PY - 2006
DA - 2006/07/15
PB - Springer Nature
SP - 1677-1694
IS - 10
VL - 11
PMID - 16850162
SN - 1360-8185
SN - 1573-675X
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2006_Hail,
author = {N Hail and H.J. Kim and R. Lotan},
title = {Mechanisms of fenretinide-induced apoptosis},
journal = {Apoptosis : an international journal on programmed cell death},
year = {2006},
volume = {11},
publisher = {Springer Nature},
month = {jul},
url = {https://doi.org/10.1007/s10495-006-9289-3},
number = {10},
pages = {1677--1694},
doi = {10.1007/s10495-006-9289-3}
}
MLA
Cite this
MLA Copy
Hail, N., et al. “Mechanisms of fenretinide-induced apoptosis.” Apoptosis : an international journal on programmed cell death, vol. 11, no. 10, Jul. 2006, pp. 1677-1694. https://doi.org/10.1007/s10495-006-9289-3.